Your metabolism has a check-engine light

My labs are normal. I am not. We hear some version of that all the time. The tiredness after lunch. The weight that settled around the middle and will not leave. The feeling of doing everything right while the numbers barely move. And a checkup that says you are fine.

Here is the uncomfortable part. By a strict definition, fewer than 1 in 10 American adults had optimal cardiometabolic health in the latest full analysis. 1 Nearly 4 in 10 meet the criteria for metabolic syndrome. 2 And in the latest national survey on it (2017 to 2020), about 8 in 10 adults with prediabetes had not been told they had it. 3 Most metabolic trouble is not rare. It is just quiet.

Your story comes first

Everything starts with how you feel. Your story tells us where to look, and it is the thing we are ultimately trying to change.

Some signs deserve a real look instead of a lecture: weight gain that lands around your middle, energy that crashes after meals, cravings that feel like they run the show, and effort that stopped paying off. None of these proves insulin resistance on its own. They are reasons to investigate, not a diagnosis.

A growing waist is one of the better-supported warning signs. Waist size relative to height flags metabolic risk better than weight or BMI alone, and a 2025 Lancet Commission said BMI should not be used by itself to diagnose obesity. 4 5

Then there is the other half of the story, the part you cannot feel. Prediabetes is usually silent. Lp(a), an inherited cholesterol particle, gives no symptoms at all. Fatty liver rarely announces itself. 6 7 8 So your symptoms point the way, and labs give them context. Sometimes the labs speak before you feel anything.

Your metabolism has a check-engine light

Blood sugar is usually the last number to cross the line. In a study that followed 6,538 British adults, fasting glucose climbed steeply only in the three years before a diabetes diagnosis. Insulin sensitivity had been sliding for five. 9 In 27,000 Japanese adults, differences showed up a full decade early. 10 And in one large study of young men, fasting glucose in the high 80s and 90s, well inside the “normal” range, already predicted more diabetes later than levels under 81 mg/dL. 11

Think of it like your car.

• Fasting insulin is the check-engine light. It can come on years early, while there is still plenty of road.
• Fasting glucose is the temperature gauge in the red. By the time it rises, insulin resistance has usually been building for years. It is too late to catch it early. It is not too late to act: in a large trial of adults with prediabetes, lifestyle changes cut new diabetes by 58% over about three years. 12
• Diabetes and heart disease are the breakdown on the shoulder of the highway. Catching the warning lights early is how you stay off the shoulder.

A fair word on fasting insulin, because I would rather you hear it from me. It is a useful clue, but insulin tests are not standardized from lab to lab, no major guideline recommends routine testing, and the international PCOS guideline advises against it in routine care. 13 14 15 So I use it the way it works best: as one clue among several, tracked over time on the same lab, and read next to how you feel. Never as a verdict on its own.

Other early clues hide in a routine panel. A high triglyceride to HDL ratio can point toward insulin resistance, though it works poorly in some groups, including African American adults. 16 17

The cholesterol tests the guideline just caught up to. The 2026 US cholesterol guideline recommends measuring Lp(a) at least once in every adult, a first for the main US cholesterol guideline. It uses ApoB, a count of the particles that actually build plaque, to find risk that a standard LDL number can miss, and it lists hs-CRP, a marker of low-grade inflammation, as a way to refine risk. 7 18 The American College of Cardiology now calls for broader hs-CRP testing, too. 19 ApoB and Lp(a) have been on our panel from the start, alongside inflammatory markers.

“Normal” is not always healthy. Your liver is the clearest example. The “normal” ALT limits many labs print were set in groups that included people with hidden liver disease. 20 The American College of Gastroenterology puts a truly healthy ALT at about 29 to 33 IU/L for men and 19 to 25 IU/L for women. 21 About a third of US adults have fatty liver disease, and the American Diabetes Association recommends a simple liver score for adults with prediabetes or diabetes. 8 22 To be fair, not every normal range is too loose. Many glucose and cholesterol cutoffs are set by real risk, and the standard testosterone range was built from healthy, nonobese men aged 19 to 39. 14 7 23 The skill is knowing which numbers to read closely, and where you sit within them.

One test needs no lab at all. Keep your waist under half your height. That is the UK’s national guidance, and it applies to men and women. 24

What drives it

Muscle is your biggest sugar sink. About 80% of the glucose cleared under insulin’s signal goes into your muscles. 25 More muscle relative to your size is linked with less insulin resistance and less prediabetes. 26 In a study of nearly 140,000 adults across 17 countries, weaker grip strength predicted death more strongly than blood pressure did. 27 Strength is not vanity. It is metabolic medicine.

Real food beats processed food, even when the nutrients match. In an NIH trial where people could eat as much as they wanted, an ultra-processed diet led them to eat about 500 more calories a day. 28 In a 2025 UK trial, people following the same healthy guidelines lost about twice as much weight when the food was minimally processed (about 2% versus 1%). 29 Fiber matters too: people who eat the most have lower rates of type 2 diabetes and heart disease, with the biggest benefit around 25 to 29 grams a day. 30

Sleep sets the table. A single week of short sleep made healthy young men less sensitive to insulin. 31 I wrote a whole piece on it: sleep is where your hormones (& health) are made.

Fitness and the liver. Cardiorespiratory fitness is one of the strongest predictors of how long people live. 32 And alcohol and metabolism meet in the liver: fatty liver driven by both now has its own name. 33

For men: “when did my metabolism switch?”

That question drew well over a thousand replies in one popular men’s forum. The top answers from the men themselves were honest: less moving, more sitting, desk jobs, beer, and long days. The research adds a hormone chapter to that story.

Men with type 2 diabetes tend to have lower testosterone, and men with higher testosterone had about 42% lower diabetes risk. 34 In one clinic study, about a third of men with type 2 diabetes had low free testosterone. 35 SHBG, the protein that carries testosterone in your blood, is one of the strongest hormone clues to diabetes risk, with genetic evidence behind it, and much of that risk runs through belly and liver fat. 36 37

Here is the twist: it runs both ways. Neal Rouzier, MD, has long taught that insulin resistance is often the real culprit, 38 and in men with obesity, losing weight brings testosterone back up, in proportion to the weight lost. 39 Low testosterone, in turn, is linked with higher diabetes risk, 34 so we look at both sides together.

What about testosterone therapy? In one two-year trial of men aged 50 to 74 with a large waist, low-normal testosterone, and prediabetes or new diabetes, everyone joined a lifestyle program. Adding testosterone cut diabetes from 21% to 12%, and 22% of the men on testosterone developed thickened blood that needed action, compared with 1% on placebo. 40 In another trial, testosterone gel alone did not prevent diabetes. 41 In a large safety trial of men at high heart risk, testosterone did not raise heart attacks or strokes, though atrial fibrillation, kidney injury, and blood clots in the lungs were more common. That is not the same as protecting the heart. 42 So weight and lifestyle do the heavy lifting, and testosterone may add to them in selected men, with monitoring.

This is also story first, then labs, in the guidelines themselves. The American Diabetes Association tells clinicians to ask men with prediabetes or diabetes about their sex drive and erections, and to check a morning testosterone if those have changed. 22 And the decline with age is gradual, about 1.6% a year for total testosterone in men 40 to 70. 43 A steeper drop is worth a closer look.

For women: the midlife shift

For women, midlife brings a metabolic plot twist. LDL cholesterol and ApoB jump within about a year of the final period, while most other risk factors simply track age. 44 45 In one four-year study of 156 women, deep belly fat rose only in the women who went through menopause, and fat burning fell. 46 Metabolic syndrome risk climbs through each year of perimenopause. 47 If your waist changed faster than your habits did, you are not imagining it. I wrote more about the transition in my first article.

Hormone therapy is part of this conversation. In large randomized trials, women on hormone therapy developed diabetes less often: 21% less in one trial and 35% less in another, in women with heart disease. It is not approved for preventing diabetes, the trials used older regimens, and its effect on belly fat and weight is small. 48 49 50 A small help with belly fat at most, and not a weight-loss treatment.

PCOS is its own story. Women with PCOS have about 27% lower insulin sensitivity whether they are lean or not, and low SHBG tracks it. 51 The international PCOS guideline says metformin should be considered for women with PCOS and a BMI of 25 or more, and that GLP-1 medicines can be considered alongside lifestyle changes under the usual obesity guidelines, with reliable contraception. 15

Holistic Hacks & Functional Facts

Build and keep your muscle. Muscle-strengthening work is linked with 10% to 17% lower rates of death, heart disease, cancer, and diabetes, with the lowest risk at about 30 to 60 minutes a week. 52 Lift, and build your cardio alongside it.

Eat enough protein, spread across your meals. Protein needs rise with age. 53 Plenty is good, more is not always better, and kidney disease changes the math.

Walk for ten minutes after you eat. In a small trial of adults with type 2 diabetes, a ten-minute walk after each meal lowered after-meal blood sugar more than a single 30-minute walk, especially after dinner. 54

Eat real food, and start with the vegetables. Minimally processed food is the best-supported swap. 28 29 In a small study of 11 people with type 2 diabetes, eating vegetables and protein before carbohydrates cut the after-meal blood sugar peak by about a third. 55

Protect your sleep and grab a tape measure. See the sleep article for the night shift, and keep your waist under half your height. 24

The trends, rated honestly.

What	The claim	What the evidence shows
Glucose monitors for everyone	See your spikes, fix your metabolism	Helpful feedback for people with prediabetes; no glucose benefit shown in healthy people, whose readings sit in range about 96% of the time. A good short experiment, not a daily score. 56 57
Berberine	“Nature’s metformin”	A real, modest blood sugar tool. In 37 trials of people with type 2 diabetes, mostly small and from China, it lowered A1c by about 0.6 of a point. 58 For weight, pooled trials found under 1 kg, so it is no stand-in for the weight-loss medicines. 59
Apple cider vinegar	Melts weight	The viral trial behind the claim was retracted in 2025. 60
Seed oils	Toxic	Scientists debate how much vegetable oils help the heart, not whether they are poison. 61 62
Keto and low-carb	The best diet, and LDL does not matter	A legitimate option for some people, about as effective as other diets, but it can raise LDL, 63 and the study claiming ApoB did not matter on keto was retracted in 2026. Check your ApoB if you go this way. 64 65
Carnivore	Reverses metabolic disease	One self-reported survey, with LDL markedly raised. 66
Fasting and eating windows	Special metabolic magic	Across 99 trials, fasting matched ordinary calorie cutting. Pick the pattern you can live with. 67 68
Creatine	Muscle, brain, and blood sugar	Modest strength gains with training in older adults; blood sugar evidence is early. 69
Zone 2 cardio	The best exercise for metabolism	A good base, not the whole house. Harder efforts matter too. 70
“Microdosing” GLP-1 medicines	Lower, steadier doses for fewer side effects and a pace you can keep	We like the thinking. Stomach side effects cluster around dose increases, which is why the trials and labels start low and go slow. 71 72 Smaller, more frequent doses aim for steadier levels, fewer peaks and valleys, and a plan people can stick with. What has not been tested is the longevity claim: no randomized trial yet, and one records study raised the question. 73

Where medicine fits

For some people, medicine belongs in the plan, and that is not a failure of willpower. In trials of adults with obesity, tirzepatide produced average weight loss of about 15% to 21% over 72 weeks, and in a company-funded head-to-head trial it beat semaglutide, 20.2% versus 13.7% on average. 71 74 Semaglutide cut the combined rate of heart attacks, strokes, and cardiovascular deaths by 20% in people with heart disease and overweight who did not have diabetes, 75 and in a phase 3 trial it improved a form of fatty liver with scarring, which it is now approved to treat. 76 GLP-1 medicines now come as pills, too: oral semaglutide was approved for weight loss in December 2025 and orforglipron in April 2026. 77 72

SGLT2 inhibitors, such as empagliflozin and dapagliflozin, are another oral option I like. They help the kidneys clear extra sugar in the urine. In large trials of people with type 2 diabetes, heart failure, or kidney disease, they cut hospital stays for heart failure and protected the kidneys, 78 and in small trials of people without diabetes they brought modest weight loss, about 1.6 kg on average. 79 They are not approved for weight loss, and in those trials a rare but serious complication, diabetic ketoacidosis, was more common, 78 so like every medicine in the plan, they are monitored.

The fine print is muscle and maintenance. On tirzepatide, about a quarter of the weight lost was lean mass. 80 Stopping brings most of the weight back. 81 82 In a year-long trial, exercise plus an older GLP-1 medicine kept weight off best. 83 That is why four nutrition and obesity societies advise checking strength, lifting, and eating enough protein on these medicines. 84 It is also why we treat the medicine as one tool inside a plan, with the labs rechecked along the way.

One practical note for women: tirzepatide and orforglipron can make oral birth control less reliable, especially after starting or raising the dose, and whether they affect oral progesterone has not been studied. If you take any oral hormone, tell your prescriber. 72 85

Bring your numbers to the conversation

A few things make any metabolic conversation more useful:

• Your recent labs, even the “normal” ones, with dates, so we can see the trend.
• Your waist and your height.
• Family history: diabetes, early heart disease, or a known high Lp(a).
• How you feel after meals, and when your energy dips.
• What you have already tried, including diets, supplements, and medicines.
• Changes you have noticed: your cycle, sleep, sex drive, or strength.

Your symptoms are the story. Your labs are the context.

Every hack and fact above is free, and I hope you use them. Lifting, walking after meals, real food, and better sleep can change a lot on their own. But a list cannot read your trend lines, spot the Lp(a) you inherited, or notice that your testosterone, your cycle, your thyroid, or your sleep has shifted. It cannot build a plan around your history, and it cannot adjust that plan as your body responds. That is where my expertise comes in. I start with your story, run labs early and often, and read them together with how you feel. Then we build a plan that fits you and monitor it closely. Nearly everyone gets a follow-up panel three to six months after the first. Sometimes the plan includes hormone therapy, testosterone therapy, a GLP-1 medicine, or an SGLT2 inhibitor. Sometimes it is something simpler than you expected. Either way, you do not have to figure it out alone.

Feel like yourself again. That is the goal, and your check-engine light is a good place to start.

Book your comprehensive consultation, or explore care for men and women at Rez.

About Kellie

Kellie Marsoobian, FNP-C, is the founder and lead provider of Rez. She is Advanced BHRT certified through WorldLink Medical, having completed the Advanced Bioidentical Hormone Replacement Therapy course series taught by Neal Rouzier, MD.

This article is general education, not personal medical advice. A qualified clinician can help assess individual symptoms and discuss suitable care.

Sources

1. O'Hearn M et al. Trends and disparities in cardiometabolic health among U.S. adults, 1999-2018. Journal of the American College of Cardiology. 2022.
2. Abohashem S et al. Trends and prevalence of the metabolic syndrome among US adults. JAMA. 2026.
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report (earlier edition; prediabetes awareness, 2017 to 2020). 2024.
4. Ashwell M et al. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors. Obesity Reviews. 2012.
5. Rubino F et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes and Endocrinology. 2025.
6. Centers for Disease Control and Prevention. Prediabetes: your chance to prevent type 2 diabetes. 2024.
7. Blumenthal RS et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. JACC. 2026.
8. Kim D et al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023. Clinical and Molecular Hepatology. 2025.
9. Tabák AG et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes. Lancet. 2009.
10. Sagesaka H et al. Type 2 diabetes: when does it start?. Journal of the Endocrine Society. 2018.
11. Tirosh A et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. New England Journal of Medicine. 2005.
12. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
13. Miller WG et al. Toward standardization of insulin immunoassays. Clinical Chemistry. 2009.
14. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026.
15. Teede HJ et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. JCEM. 2023.
16. McLaughlin T et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine. 2003.
17. Sumner AE et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Archives of Internal Medicine. 2005.
18. Soffer DE et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. 2024.
19. Mensah GA et al. Inflammation and cardiovascular disease: 2025 ACC Scientific Statement. JACC. 2026.
20. Prati D et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine. 2002.
21. Kwo PY et al. ACG clinical guideline: evaluation of abnormal liver chemistries. American Journal of Gastroenterology. 2017.
22. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes-2026. Diabetes Care. 2026.
23. Travison TG et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. JCEM. 2017.
24. National Institute for Health and Care Excellence. Overweight and obesity management (NG246). 2025.
25. DeFronzo RA et al. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009.
26. Srikanthan P et al. Relative muscle mass is inversely associated with insulin resistance and prediabetes. JCEM. 2011.
27. Leong DP et al. Prognostic value of grip strength: findings from the PURE study. Lancet. 2015.
28. Hall KD et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial. Cell Metabolism. 2019.
29. Dicken SJ et al. Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial. Nature Medicine. 2025.
30. Reynolds A et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019.
31. Buxton OM et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. 2010.
32. Mandsager K et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open. 2018.
33. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023.
34. Ding EL et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006.
35. Dhindsa S et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. JCEM. 2004.
36. Ding EL et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine. 2009.
37. Stangl TA et al. Association between low SHBG and increased risk of type 2 diabetes is mediated by increased visceral and liver fat. Diabetes. 2024.
38. WorldLink Medical. Part 3 in the BHRT Education Series: Solve Troubling Symptoms (course description). 2025. Cited only for the teaching that insulin resistance, not testosterone, is often the culprit.
39. Corona G et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology. 2013.
40. Wittert G et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM). Lancet Diabetes and Endocrinology. 2021.
41. Bhasin S et al. Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial. JAMA Internal Medicine. 2024.
42. Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023.
43. Feldman HA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. JCEM. 2002.
44. Matthews KA et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?. JACC. 2009.
45. El Khoudary SR et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the AHA. Circulation. 2020.
46. Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity. 2008.
47. Janssen I et al. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Archives of Internal Medicine. 2008.
48. Margolis KL et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004.
49. Kanaya AM et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine. 2003.
50. The North American Menopause Society (now The Menopause Society) Advisory Panel. The 2022 hormone therapy position statement. Menopause. 2022.
51. Cassar S et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction. 2016.
52. Momma H et al. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases. British Journal of Sports Medicine. 2022.
53. Bauer J et al. Evidence-based recommendations for optimal dietary protein intake in older people: PROT-AGE. JAMDA. 2013.
54. Reynolds AN et al. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes than advice that does not specify timing. Diabetologia. 2016.
55. Shukla AP et al. Food order has a significant impact on postprandial glucose and insulin levels. Diabetes Care. 2015.
56. Shah VN et al. Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. JCEM. 2019.
57. Liao X et al. Continuous glucose monitoring in non-diabetic populations: a systematic review of observational and interventional studies with meta-analysis. European Journal of Medical Research. 2026.
58. Xie W et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Frontiers in Pharmacology. 2022.
59. Elahi Vahed I et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. International Journal of Obesity. 2026.
60. Abou-Khalil R et al. Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity. BMJ Nutrition, Prevention and Health. 2024. Retracted September 23, 2025 (retraction notice PMID 41789013).
61. Sacks FM et al. Dietary fats and cardiovascular disease: a presidential advisory from the AHA. Circulation. 2017.
62. Ramsden CE et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ. 2016.
63. Gardner CD et al. Effect of a ketogenic diet versus Mediterranean diet on glycated hemoglobin in individuals with prediabetes and type 2 diabetes mellitus: the Keto-Med randomized crossover trial. American Journal of Clinical Nutrition. 2022.
64. Gardner CD et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss: the DIETFITS randomized clinical trial. JAMA. 2018.
65. Soto-Mota A et al. Longitudinal data from the KETO-CTA study: plaque predicts plaque, ApoB does not. JACC Advances. 2025. Retracted in 2026; cited only to note the retraction.
66. Lennerz BS et al. Behavioral characteristics and self-reported health status among 2029 adults consuming a "carnivore diet". Current Developments in Nutrition. 2021.
67. Semnani-Azad Z et al. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis. BMJ. 2025.
68. Lowe DA et al. Effects of time-restricted eating on weight loss and other metabolic parameters: the TREAT randomized clinical trial. JAMA Internal Medicine. 2020.
69. Chilibeck PD et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access Journal of Sports Medicine. 2017.
70. Storoschuk KL et al. Much ado about zone 2: a narrative review assessing the efficacy of zone 2 training. Sports Medicine. 2025.
71. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
72. U.S. Food and Drug Administration. Orforglipron tablets prescribing information. 2026.
73. Murugadoss K et al. Sustained low-dose semaglutide is linked to broad-spectrum cardiometabolic benefits (preprint, not peer reviewed). Preprints. 2026.
74. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025.
75. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
76. Sanyal AJ et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine. 2025.
77. Novo Nordisk. FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults. 2025.
78. Salah HM et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes: systematic review and meta-analysis of randomized placebo-controlled trials. American Heart Journal. 2021.
79. Cho YK et al. Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. Journal of Obesity and Metabolic Syndrome. 2021.
80. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism. 2025.
81. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
82. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
83. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.
84. Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA, and The Obesity Society. Obesity Pillars. 2025.
85. Viana DPDC et al. Tirzepatide and oral progestogens: a hypothesis-generating review of a biologically plausible pharmacokinetic interaction. Maturitas. 2026.